Literature DB >> 15658071

Use of colistin in the treatment of multiple-drug-resistant gram-negative infections.

David Berlana1, J M Llop, E Fort, M B Badia, R Jódar.   

Abstract

PURPOSE: The use of colistin for the treatment of infections caused by multiple-drug-resistant (MDR) gram-negative microorganisms was studied.
METHODS: The efficacy of colistin for treating infections caused by MDR gram-negative microorganisms and the development of renal toxicity were studied in hospitalized adult patients in Spain. Patients treated between January 2001 and October 2001 were included.
RESULTS: Over the study period, 71 courses of inhaled colistin, 12 courses of i.v. or intramuscular (i.m.) colistin, and 2 courses of intrathecal colistin were administered to 80 patients. All were infected by MDR organisms: 69 (86%) by Acinetobacter baumannii and 11 (14%) by Pseudomonas aeruginosa. In 41 patients (51%), the episodes were caused by A. baumannii strains susceptible exclusively to colistin. The causative organisms were cleared in 92% of the patients from whom posttreatment repeat specimens were obtained. The in-hospital mortality rate was 18% (14 patients). There were no significant changes in mean serum urea or creatinine concentrations in patients receiving i.v. or i.m. therapy.
CONCLUSION: Colistin was used in 80 patients infected with A. baumannii or P. aeruginosa and appeared to be efficacious and safe.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15658071     DOI: 10.1093/ajhp/62.1.39

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  41 in total

1.  Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats.

Authors:  Sandrine Marchand; Patrice Gobin; Julien Brillault; Sara Baptista; Christophe Adier; Jean-Christophe Olivier; Olivier Mimoz; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

2.  Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration.

Authors:  J Li; C R Rayner; R L Nation; R Deans; R Boots; N Widdecombe; A Douglas; J Lipman
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

3.  Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin.

Authors:  Aspasia Katragkou; Emmanuel Roilides
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

Review 4.  The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.

Authors:  Matthew E Falagas; Sofia K Kasiakou; Sotirios Tsiodras; Argyris Michalopoulos
Journal:  Clin Med Res       Date:  2006-06

5.  Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.

Authors:  Phillip J Bergen; Jian Li; Craig R Rayner; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 6.  Acinetobacter pneumonia: a review.

Authors:  Joshua D Hartzell; Andrew S Kim; Mark G Kortepeter; Kimberly A Moran
Journal:  MedGenMed       Date:  2007-07-05

Review 7.  Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia.

Authors:  G Christopher Wood; Joseph M Swanson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 9.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

10.  Isolation and identification of a Paenibacillus polymyxa strain that coproduces a novel lantibiotic and polymyxin.

Authors:  Zengguo He; Duygu Kisla; Liwen Zhang; Chunhua Yuan; Kari B Green-Church; Ahmed E Yousef
Journal:  Appl Environ Microbiol       Date:  2006-10-27       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.